Detalhe da pesquisa
1.
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Breast Cancer Res
; 26(1): 32, 2024 02 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38408999
2.
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial.
Lancet Oncol
; 22(6): 883-892, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989559
3.
Research-based PAM50 signature and long-term breast cancer survival.
Breast Cancer Res Treat
; 179(1): 197-206, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31542876
4.
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer.
J Transl Med
; 18(1): 214, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32466781
5.
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Breast Cancer Res
; 26(1): 46, 2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38481291
6.
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Oral Oncol
; 135: 106219, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36279618
7.
miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study.
Cancer Epidemiol Biomarkers Prev
; 28(9): 1525-1533, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186261
8.
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
Cell Stem Cell
; 22(6): 951-959.e3, 2018 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29859176
9.
Isolation and structure determination of malevamide E, a dolastatin 14 analogue, from the marine cyanobacterium Symploca laete-viridis.
J Nat Prod
; 71(5): 750-4, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18361518